je.st
news
Home
› Trevena Announces Successful End-Of-Phase 2 Meeting With FDA And Outlines Phase 3 Program For Oliceridine
Trevena Announces Successful End-Of-Phase 2 Meeting With FDA And Outlines Phase 3 Program For Oliceridine
2016-05-03 02:52:15| drugdiscoveryonline News Articles
Trevena, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors, recently announced the successful completion of the End-of-Phase 2 Meeting process with the United States Food and Drug Administration (FDA)
Tags: for
program
meeting
successful
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||